OBJECTIVE To determine the effects of dapagliflozin in patients with heart failure (HF) and type 2 diabetes mellitus (T2DM) on left ventricular (LV) remodeling using cardiac MRI. RESEARCH DESIGN AND METHODS We randomized 56 patients with T2DM and HF with LV systolic dysfunction to dapagliflozin 10 mg daily or placebo for 1 year, on top of usual therapy. The primary end point was difference in LV end-systolic volume (LVESV) using cardiac MRI. Key secondary end points included other measures of LV remodeling and clinical and biochemical parameters. RESULTS In our cohort, dapagliflozin had no effect on LVESV or any other parameter of LV remodeling. However, it reduced diastolic blood pressure and loop diuretic requirements while increasing hemoglobin, hematocrit, and ketone bodies. There was a trend toward lower weight. CONCLUSIONS We were unable to determine with certainty whether dapagliflozin in patients with T2DM and HF had any effect on LV remodeling. Whether the benefits of dapagliflozin in HF are due to remodeling or other mechanisms remains unknown.

中文翻译：

---

Dapagliflozin 与安慰剂对糖尿病和心力衰竭患者左心室重塑的影响：REFORM 试验。

目的 使用心脏 MRI 确定达格列净对心力衰竭 (HF) 和 2 型糖尿病 (T2DM) 患者左心室 (LV) 重塑的影响。研究设 主要终点是使用心脏 MRI 的 LV 收缩末期容积 (LVESV) 的差异。关键的次要终点包括 LV 重塑以及临床和生化参数的其他测量。结果 在我们的队列中，达格列净对 LVESV 或任何其他 LV 重构参数没有影响。然而，它降低了舒张压和袢利尿剂的需求，同时增加了血红蛋白、红细胞比容和酮体。有降低体重的趋势。结论 我们无法确定达格列净在 T2DM 和 HF 患者中是否对 LV 重塑有任何影响。达格列净在 HF 中的益处是否是由于重塑或其他机制仍然未知。